FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2564763502> ?p ?o ?g. }

• W2564763502 abstract "PURPOSE: Triple negative breast cancer (TNBC) is the most aggressive and fatal form of breast cancer. TNBC has no effective therapies since it is not driven by the estrogen (ER), progesterone (PR), and human epidermal growth factor type 2 (Her2/Neu) receptors for which there are targeted drugs. Human epidermal growth factor receptors (EGFR) are overexpressed in 92% of TNBC cases, however, anti-EGFR therapies are ineffective. Monomeric G-proteins that regulate cell proliferation, angiogenesis, migration and apoptosis operate downstream of EGFR and other signal transduction pathways. Polyisoprenylated methylated protein methyl esterase (PMPMEase) metabolizes monomeric G-proteins, allowing them to function properly. PMPMEase is overexpressed in many cancers and may serve as a biomarker and target for cancer therapy. We have synthesized polyisoprenylated cysteinyl amide inhibitors that may inhibit PMPMEase and/or disrupt polyisoprenylated protein function. We hypothesize that the PCAIs will promote anti-tumorigenic effects, inducing apoptosis, while inhibiting cell survival, proliferation, migration, and invasion. The purpose of this study was to test the effectiveness of PCAIs against the biological hallmarks of TNBC. METHODS: Four TNBC cell lines were treated with the PCAIs and analyzed for their effects on cell survival, viability, F-actin organization, cell migration and apoptosis. RESULTS: Treatment of TNBC cells with the PCAIs resulted in a concentration-dependent death of the TNBC cells with EC50 values ranging from 2.13 to 2.78 μM for NSL-BA-040 and NSL-BA-055 in media containing 5% FBS. AO/EB staining revealed early apoptosis at 1 μM. NSL-RD-036 inhibited MDA-MB-231 cell migration by 71% (163±10.7 cells in control versus 47±6.9 in treated (±SEM, N = 3). PCAIs induced complete disruption of F-actin filament organization at 2 μM in MDA-MB-468 cells. CONCLUSION: The PCAIs’ ability to induce apoptosis, and inhibit cell migration by disrupting F-actin filaments suggest that their potential therapeutic value could involve the inhibition of TNBC tumor growth, metastasis, and angiogenesis, which are all essential hallmarks for breast cancer progression. The PCAIs may ultimately fill the targeted therapy void in TNBC therapy. Citation Format: Olufisayo O. Salako, Rosemary A. Poku, Augustine T. Nkembo, Typhon Mazu, Hernan Flores-Rozas, Nazarius S. Lamango. Polyisoprenylated cysteinyl amide inhibitors exhibit anti-tumor effects in human breast cancer cell lines. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 660. doi:10.1158/1538-7445.AM2015-660" @default.
• W2564763502 created "2017-01-06" @default.
• W2564763502 creator A5013398839 @default.
• W2564763502 creator A5018272549 @default.
• W2564763502 creator A5052540246 @default.
• W2564763502 creator A5056717418 @default.
• W2564763502 creator A5060820865 @default.
• W2564763502 creator A5074692638 @default.
• W2564763502 date "2015-08-01" @default.
• W2564763502 modified "2023-09-27" @default.
• W2564763502 title "Abstract 660: Polyisoprenylated cysteinyl amide inhibitors exhibit anti-tumor effects in human breast cancer cell lines" @default.
• W2564763502 doi "https://doi.org/10.1158/1538-7445.am2015-660" @default.
• W2564763502 hasPublicationYear "2015" @default.
• W2564763502 type Work @default.
• W2564763502 sameAs 2564763502 @default.
• W2564763502 citedByCount "0" @default.
• W2564763502 crossrefType "proceedings-article" @default.
• W2564763502 hasAuthorship W2564763502A5013398839 @default.
• W2564763502 hasAuthorship W2564763502A5018272549 @default.
• W2564763502 hasAuthorship W2564763502A5052540246 @default.
• W2564763502 hasAuthorship W2564763502A5056717418 @default.
• W2564763502 hasAuthorship W2564763502A5060820865 @default.
• W2564763502 hasAuthorship W2564763502A5074692638 @default.
• W2564763502 hasConcept C121608353 @default.
• W2564763502 hasConcept C170493617 @default.
• W2564763502 hasConcept C185592680 @default.
• W2564763502 hasConcept C190283241 @default.
• W2564763502 hasConcept C2777506169 @default.
• W2564763502 hasConcept C2779438470 @default.
• W2564763502 hasConcept C2780110267 @default.
• W2564763502 hasConcept C502942594 @default.
• W2564763502 hasConcept C530470458 @default.
• W2564763502 hasConcept C53227056 @default.
• W2564763502 hasConcept C54355233 @default.
• W2564763502 hasConcept C55493867 @default.
• W2564763502 hasConcept C62112901 @default.
• W2564763502 hasConcept C84606932 @default.
• W2564763502 hasConcept C86803240 @default.
• W2564763502 hasConceptScore W2564763502C121608353 @default.
• W2564763502 hasConceptScore W2564763502C170493617 @default.
• W2564763502 hasConceptScore W2564763502C185592680 @default.
• W2564763502 hasConceptScore W2564763502C190283241 @default.
• W2564763502 hasConceptScore W2564763502C2777506169 @default.
• W2564763502 hasConceptScore W2564763502C2779438470 @default.
• W2564763502 hasConceptScore W2564763502C2780110267 @default.
• W2564763502 hasConceptScore W2564763502C502942594 @default.
• W2564763502 hasConceptScore W2564763502C530470458 @default.
• W2564763502 hasConceptScore W2564763502C53227056 @default.
• W2564763502 hasConceptScore W2564763502C54355233 @default.
• W2564763502 hasConceptScore W2564763502C55493867 @default.
• W2564763502 hasConceptScore W2564763502C62112901 @default.
• W2564763502 hasConceptScore W2564763502C84606932 @default.
• W2564763502 hasConceptScore W2564763502C86803240 @default.
• W2564763502 hasLocation W25647635021 @default.
• W2564763502 hasOpenAccess W2564763502 @default.
• W2564763502 hasPrimaryLocation W25647635021 @default.
• W2564763502 hasRelatedWork W2037578345 @default.
• W2564763502 hasRelatedWork W2089021108 @default.
• W2564763502 hasRelatedWork W2139609805 @default.
• W2564763502 hasRelatedWork W2330715868 @default.
• W2564763502 hasRelatedWork W2443950890 @default.
• W2564763502 hasRelatedWork W2567652734 @default.
• W2564763502 hasRelatedWork W2740340845 @default.
• W2564763502 hasRelatedWork W2740751626 @default.
• W2564763502 hasRelatedWork W2746773004 @default.
• W2564763502 hasRelatedWork W2757282303 @default.
• W2564763502 hasRelatedWork W2770362455 @default.
• W2564763502 hasRelatedWork W2778912499 @default.
• W2564763502 hasRelatedWork W2793670714 @default.
• W2564763502 hasRelatedWork W2891559802 @default.
• W2564763502 hasRelatedWork W2913504125 @default.
• W2564763502 hasRelatedWork W2948523827 @default.
• W2564763502 hasRelatedWork W2953841009 @default.
• W2564763502 hasRelatedWork W3037128933 @default.
• W2564763502 hasRelatedWork W3134479811 @default.
• W2564763502 hasRelatedWork W3178489426 @default.
• W2564763502 isParatext "false" @default.
• W2564763502 isRetracted "false" @default.
• W2564763502 magId "2564763502" @default.
• W2564763502 workType "article" @default.